Factors related to outcomes in lupus-related protein-losing enteropathy.
10.3904/kjim.2015.30.6.906
- Author:
Doo Ho LIM
1
;
Yong Gil KIM
;
Seung Hyeon BAE
;
Soomin AHN
;
Seokchan HONG
;
Chang Keun LEE
;
Bin YOO
Author Information
1. Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. bestmd2000@amc.seoul.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Protein-losing enteropathies;
Lupus erythematosus, systemic;
Hypercholesterolemia
- MeSH:
Adult;
Aged;
Biomarkers/blood;
Cholesterol/blood;
Drug Therapy, Combination;
Edema/diagnosis/drug therapy/*etiology;
Female;
Glucocorticoids/therapeutic use;
Humans;
Hypoalbuminemia/diagnosis/drug therapy/*etiology;
Immunosuppressive Agents/therapeutic use;
Lupus Erythematosus, Systemic/*complications/diagnosis/drug therapy;
Male;
Middle Aged;
Protein-Losing Enteropathies/diagnosis/drug therapy/*etiology;
Remission Induction;
Risk Factors;
Serum Albumin/metabolism;
Tertiary Care Centers;
Time Factors;
Treatment Outcome
- From:The Korean Journal of Internal Medicine
2015;30(6):906-912
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Protein-losing enteropathy (PLE), characterized by severe hypoalbuminemia and peripheral edema, is a rare manifestation of systemic lupus erythematosus. This present study aimed to identify the distinctive features of lupus-related PLE and evaluate the factors related to the treatment response. METHODS: From March 1998 to March 2014, the clinical data of 14 patients with lupus PLE and seven patients with idiopathic PLE from a tertiary center were reviewed. PLE was defined as a demonstration of protein leakage from the gastrointestinal tract by either technetium 99m-labelled human albumin scanning or fecal alpha1-antitrypsin clearance. A positive steroid response was defined as a return of serum albumin to > or = 3.0 g/dL within 4 weeks after initial steroid monotherapy, and remission as maintenance of serum albumin > or = 3.0 g/dL for at least 3 months. A high serum total cholesterol level was defined as a level of > or = 240 mg/dL. RESULTS: The mean age of the lupus-related PLE patients was 37.0 years, and the mean follow-up duration was 55.8 months. Significantly higher erythrocyte sedimentation rate and serum total cholesterol levels were found for lupus PLE than for idiopathic PLE. Among the 14 patients with lupus PLE, eight experienced a positive steroid response, and the serum total cholesterol level was significantly higher in the positive steroid response group. A positive steroid response was associated with an initial high serum total cholesterol level and achievement of remission within 6 months. CONCLUSIONS: In lupus-related PLE, a high serum total cholesterol level could be a predictive factor for the initial steroid response, indicating a good response to steroid therapy alone.
